

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/086107 A2

(51) International Patent Classification⁷: C12N 5/08, 5/02, A61K 35/39, 35/48, C12Q 1/02, A61P 5/48

(74) Agents: WEICKMANN, Franz, Albert et al.; Weickmann & Weickmann, Postfach 86 08 20, 81635 München (DE).

(21) International Application Number: PCT/EP02/04362

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 19 April 2002 (19.04.2002)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

(26) Publication Language: English

Published:

— without international search report and to be republished upon receipt of that report

(30) Priority Data:
60/284,531 19 April 2001 (19.04.2001) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicants (*for all designated States except US*):
DEVELOGEN AKTIENGESELLSCHAFT FÜR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG [DE/DE]; Rudolf-Wissell-Strasse 28, 37079 Göttingen (DE). INSTITUT FÜR PFLANZENGENETIK UND KULTURPFLANZENFORSCHUNG [DE/DE]; Corrensstrasse 3, 06466 Gatersleben (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): WOBUS, Anna, M. [DE/DE]; Liebigweg 7, 06466 Gatersleben (DE). ST-ONGE, Luc [CA/DE]; Rautenbreite 5, 37077 Göttingen (DE). BLYSZCZUK, Przemyslaw [PL/DE]; Corrensstrasse 4a, 06466 Gatersleben (DE). HOFFMANN, Ursula [DE/DE]; Schedener Weg 28, 37127 Jühnde (DE).



WO 02/086107 A2

(54) Title: A METHOD FOR DIFFERENTIATING STEM CELLS INTO INSULIN-PRODUCING CELLS

(57) Abstract: The present invention relates a novel method for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical (particularly diabetes) field that directly arise from the method of the invention. Additionally, the present invention relates to applications for identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.

- 1 -

A Method For Differentiating Stem Cells into Insulin-Producing Cells

Description

5

FIELD OF THE INVENTION

The present invention relates to methods for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined mediums and optimally, activating one or more genes involved in beta-cell differentiation. The present invention provides means for treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, for instance, but not limited to, diabetes mellitus, hyperglycaemia and impaired glucose tolerance, by transplanting said insulin-producing cells into diabetic animals and humans. The methods can further be used to generate cells for the identification and characterisation of compounds which stimulate beta-cell differentiation, insulin secretion or glucose responsiveness. Differentiated insulin-producing cells can also be used to study the toxic and other effects of exogenous compounds on beta-cell function.

BACKGROUND OF THE INVENTION

Diabetes, hyperglycaemia and impaired glucose tolerance are endocrine disorders characterised by inadequate production or use of insulin, which affects the metabolism of carbohydrates, proteins, and lipids resulting in abnormal levels of glucose in the blood. Diabetes is a heterogeneous disease that can be classified into two major group: Type 1 diabetes (also known as Insulin-dependent diabetes, IDDM, type I, juvenile diabetes) and Type 2 diabetes (Noninsulin-dependent diabetes, NIDDM, type II, maturity-onset diabetes).

- 2 -

The functional unit of the endocrine pancreas is the islet of Langerhans which are scattered throughout the exocrine portion of the pancreas and are composed of four cell types: alpha-, beta-, delta-, and PP-cells. Beta-cells produce insulin, represent the majority of the endocrine cells and form the core of the islets while alpha-cells secrete glucagon and are located in the periphery. Delta-cells and PP-cells are less numerous and secrete somatostatin and a pancreatic polypeptide respectively. Insulin and glucagon are key regulators of blood glucose levels. Insulin lowers blood glucose levels by increasing its cellular uptake and conversion into glycogen. Glucagon elevates blood glucose levels by intervening in the breakdown of liver glycogen. Type 1 diabetes is characterised by an autoimmune destruction of insulin-producing beta-cells. Type 2 diabetes is characterised by insulin resistance and impaired glucose tolerance where insulin is not efficiently used or is produced in insufficient amounts by the beta-cells. Therefore, type 2 patients often require additional insulin to regulate blood glucose levels. Consequently, there is little therapeutic difference in the administration of insulin between type 1 and type 2 diabetic patients (see Fajans in Diabetes Mellitus fifth editions; Porte and Sherwin, ed; Appleton & Lange pub. 1997, 1423pp). Individuals afflicted with diabetes must inject themselves up to six times a day with insulin.

Despite insulin injections, diabetic patients develop complications and their susceptibility to strokes, blindness, amputations, kidney and cardiovascular diseases is greatly increased while their life expectancy is shortened (Nathan (1993) N. Engl. J. Med. 328:1676-1685; Group, T. D. C. a. C. T. R. (1993) N. Engl. J. Med. 329:977-986). Replacement of absent insulin-producing cells by transplantation of islets of Langerhans or insulin-producing cells is one promising therapeutic option (Luzi *et al.* (1996) J. Clin. Invest. 97:2611-2618; Bretzel *et al.* (1996) Ther. Umsch. 53:889-901) However, the availability of human donor tissue for transplantation is severely limited. An alternative option would be the use of animal tissues from pigs but serious technical problems such as long term

immunosuppression and the risk of transferring a porcine pathogen such as porcine endogenous retrovirus into the human population must be solved (Butler *et al.* (1998) *Nature* **391**:320-324; Bach *et al.* (1998) *Nature Med.* **4**:141-144; Shapiro *et al.* (2000) *N. Engl. J. Med.* **343**:230-238). One solution to this problem would be to generate a human "surrogate cell" capable of assuming the functions of the missing or malfunctioning beta-cell. Therefore, there exists a need for producing an unlimited amount of surrogate insulin-producing cells for transplantation into diabetic patients. The present invention satisfies this need by providing an easy method for inducing the differentiation of stem cells into functional insulin-producing cells.

Stem cells are undifferentiated or immature cells that can give rise to various specialised cell types. Once differentiated or induced to differentiate, stem cells can be used to repair damaged and malfunctioning organs. Stem cells can be of embryonic or adult origin. Adult or somatic stem cells have been identified in numerous different tissues such as muscle, bone marrow, liver, and brain (Vescovi and Snyder (1999) *Brain Pathol.*, **9**:569-598; Seale and Rudnicki (2000) *Dev. Biol.*, **218**:115-124). In the pancreas, several indications suggest that stem cells are also present within the adult tissue (Gu and Sarvetnick (1993) *Development*, **118**:33-46; Bouwens (1998) *Microsc Res Tech*, **43**:332-336; Bonner-Weir (2000) *J. Mol. Endocrin.*, **24**:297-302). However, this population is poorly defined and represents a very small percentage of cells in the pancreas.

Embryonic stem cells can be isolated from the inner cell mass of pre-implantation embryos (ES cells) or from the primordial germ cells found in the genital ridges of post-implanted embryos (EG cells). When grown in special culture conditions such as spinner culture or hanging drops, both ES and EG cells aggregate to form embryoid bodies (EB). EBs are composed of various cell types similar to those present during embryogenesis. When cultured in appropriate media, EB can be used to

- 4 -

generate *in vitro* differentiated phenotypes, such as extraembryonic endoderm, hematopoietic cells, neurons, cardiomyocytes, skeletal muscle cells, and vascular cells. No method has been described so far that allows EB to efficiently differentiate into insulin-producing cells.

5

Soria and colleagues describe a method for selecting insulin-secreting cell clones from ES cells using a cell-trapping system, wherein cells are transfected with a plasmid allowing the expression of neomycin resistance gene under the control of the regulatory region of the human insulin gene. Cells from an insulin-secreting cell clone were implanted in the spleen of diabetic mice. The implanted cells can normalise blood glucose levels and restore body weight in the treated animals (Soria *et al.* (2000) *Diabetes* 49:157-162). A disadvantage of this selection method is, however, its low efficiency.

15

Lumelsky and colleagues (Lumelsky *et al.* (May 2001), *Science* 292: 1389-1394) have generated insulin-expressing cells from mouse ES cells. ES cells are expanded on a gelatine-coated tissue culture surface without feeder cells and in the presence of LIF. Then, embryoid bodies are generated in suspension in ES cell medium in the absence of LIF. In a further stage nestin-positive cells are selected in a serum-free medium (ITSFn) on tissue culture surface. Resulting pancreatic endocrine progenitor cells are expanded and the differentiation and morphogenesis of insulin-secreting islet clusters is induced. However, the insulin-secreting islet clusters did not restore normal blood glucose levels when transplanted into diabetic mice.

25

Assady *et al.* (August 2001), *Diabetes*, 50:1-7) describe a spontaneous *in vitro* differentiation of pluripotent human embryonic stem cells into cells having the characteristics of insulin-producing cells. Secretion of insulin into the medium was observed in a differentiation-dependent manner and was associated with the appearance of other β -cell markers. However, the

efficiency of differentiation was low with only 1-3% of differentiated cells positive for insulin.

The present invention is aimed at inducing the differentiation of ES cells by activation of specific genes into insulin-producing cells and is therefore different from the methods of the prior art designed to select such cells.

In recent years, several genes have been shown to be essential for the generation of pancreatic endocrine cells during embryogenesis (Edlund 5 (1998) *Diabetes*, **47**:1817-1823; St-Onge *et al.* (1999) *Curr. Opin. Genet. Dev.*, **9**:295-300). Pancreas development involves a series of inductive signals emanating from the surrounding mesodermic tissues and transcription factors expressed in the pancreatic epithelium. The homeobox containing transcription factor Pdx1 (also referred to Idx1, STF1, IPF1) is 10 expressed in all cells of the pancreatic buds during development and will become restricted to the beta-cells in adult animals. Pdx1 mutant mice do not develop any exocrine nor endocrine tissue and do not have any pancreas (Jonsson *et al.* (1994) *Nature*, **371**:606-609; Ahlgren *et al.* 15 (1996) *Development*, **122**:1409-1416; Offield *et al.* (1996) *Development*, **122**:983-995). The basic helix-loop-helix transcription factor neurogenin3 20 (ngn3) is required for the specification of the early endocrine precursor in the pancreatic epithelium and is downregulated once endocrine differentiation begins (Apelqvist *et al.* (1999) *Nature*, **400**:877-881; Jensen *et al.* (2000) *Diabetes*, **49**:163-176; Gradwohl *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A.*, **97**:1607-1611). Two members of the Pax gene family, 25 Pax4 and Pax6, are essential for proper differentiation of endocrine cells in the pancreas (Sosa-Pineda *et al.* (1997) *Nature*, **386**:399-402; St-Onge *et al.* (1997) *Nature*, **397**:406-409; Sanders *et al.* (1997) *Genes Dev.*, **11**:1662-1673). Both Pax genes are expressed early in development in a 30 subset of endocrine precursor cells of the pancreatic epithelium, before differentiation of the mature hormone-producing cells. Mice lacking Pax4 fail to develop any beta-cells and are diabetic while the alpha-cell

- 6 -

population is absent in Pax6 mutant mice. Nkx2.2, Nkx6.1, Nkx6.2, Isl1, and NeuroD are also among essential transcription factors required for the proper differentiation and function of beta-cells.

5 Several animal models for beta-cell regeneration suggest that the mechanisms involved in beta-cell differentiation in adult organism are similar to the mechanisms involved in beta-cell differentiation during embryogenesis. Gu and Savernick have established a model system for studying pancreatic islet and beta-cell regeneration in transgenic mice bearing the interferon-gamma (IFN-gamma) gene expressed in pancreatic islets. In this model, new islet cells (i.e. beta-, alpha-, delta- and PP-cells) are formed continuously from pancreatic duct cells (Gu and Savernick 10 (1993) Development, 118:33-46). They show that duct cell proliferation and the duct-associated islet formation in IFN-gamma transgenic mice is recapitulating islet formation during development and requires the expression of Pax4, Pax6 and Pdx1 genes. Although a link exists between the genes involved in islet regeneration in adult animals and beta-cell differentiation during embryogenesis, it has not been shown in the prior art 15 that activation of such genes in stem cells can induce the differentiation that activation of such genes in stem cells can induce the differentiation 20 into insulin-producing cells.

SUMMARY OF THE INVENTION

The present invention relates a novel method for differentiating stem cells 25 into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical and diabetes field that directly arise from the method of the invention. Additionally, the present invention relates to applications for 30 identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Before the present methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

A technical problem underlying the present invention is to provide a method for generating insulin-producing cells for transplantation in patients afflicted with pancreatic diseases, such as for example but not limited to, hyperglycaemia, impaired glucose tolerance, gestational diabetes, and diabetes mellitus. The solution to said technical problem is achieved by the embodiments characterised in the claims.

Thus, the present invention relates to methods for differentiating stem cells into insulin-producing cells comprising

- (a) Activating one or more pancreatic genes in a stem cell
- (b) Aggregating said cells to form embryoid bodies

- 8 -

- (c) Cultivating embryoid bodies in specific differentiation media enhancing beta-cell differentiation
- (d) Identification and selection of insulin-producing cells and of pancreatic cells.

5

In connection with the present invention, the term "stem cells" denotes an undifferentiated or immature embryonic, adult or somatic cells that can give rise to various specialised cell types. The term stem cells can includes embryonic stem cells (ES) and primordial germ cells (EG) cells of human or animal origin. Isolation and culture of such cells is well known to those skilled in the art (Thomson *et al.* (1998) *Science* **282**:1145–1147; Shambrott *et al.* (1998) *Proc. Natl. Acad. Sci. USA* **95**:13726–13731; US 6,090,622; US 5,914,268; WO 0027995; Notarianni *et al.* (1990) *J. Reprod. Fert.* **41**:51-56; Vassilieva *et al.* (2000) *Exp. Cell. Res.* **258**:361-373). The term "stem cells" can include neural progenitor cells from embryonic, fetal or adult neural tissues. Isolation and culture of such cells is well known to those skilled in the art (Rao (Ed.), *Stem Cells and CNS Development*, Humana Press Inc., New Jersey (2001); Fedoroff and Richardson (Eds.), *Protocols for Neural Cell Culture*, Humana Press Inc., 3rd edition, New Jersey, (2001)).

10

15

20

The term "insulin-producing cell" means a cell capable of expressing, producing, and secreting insulin.

25

30

The term "cultivation medium" means a suitable medium capable of supporting growth and differentiation of stem cells, preferably ES and EG cells. Examples of suitable culture media in practising the present invention are prepared with a base of Dulbecco's modified Eagle's medium (DMEM, Life Technologies) supplemented with 15% heat-inactivated foetal calf serum (FCS, Gibco), and additives, such as 2 mM L-glutamine (Gibco), 5 x 10⁻⁶M β-mercaptoethanol (Serva) and 1:100 non-essential amino acids (Gibco). Another example is a culture medium comprising Iscove's modified

- 9 -

Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2 mM L-glutamine (Gibco), 1:100 non-essential amino acids (Gibco) and 450 μ M α -monothioglycerol (Sigma). For routine cultures, ES cells are grown on a feeder layer of embryonic fibroblasts inactivated by treatment with 100 μ g/ml mitomycin C for 3 hours.

The term "differentiation medium" means a suitable medium for inducing the differentiation of stem cells into insulin-producing cells. Examples of suitable culture media in practising the present invention are prepared with a base of Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% fetal calf serum (FCS), 2mM L-glutamine, 1:100 non-essential amino acids and 450 μ M α -monothioglycerol (Sigma). In addition, such medium can contain between 1 ng/ml and 100 μ g/ml, preferably 10 ng/ml Epithelial Growth Factor (EGF); between 1ng/ml and 100 μ g/ml, preferably 2 ng/ml basic Fibroblast Growth Factor (bFGF); between 1 nM and 1 mM, preferably 20 nM progesterone; between 10 ng/ml and 100 μ g/ml, preferably 100 ng/ml Growth hormone; between 1 nM and 100 μ M, preferably 5 nM follistatin (R&D); or between 1 and 100 nM, preferably 2nM activin (R&D). Another example of suitable culture media in practising the present invention is prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies) supplemented with between 100 ng/ml and 100 μ g/ml, preferably 5 μ g/ml insulin; between 1 nM and 100 nM, preferably 30 nM sodium selenite; between 100 ng/ml and 500 μ g/ml, preferably 50 μ g/ml transferrin; between 100 ng/ml and 100 μ g/ml, preferably 5 μ g/ml fibronectin. Yet another example of suitable culture media in practising the present invention is prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies) supplemented with between 100 ng/ml and 100 μ g/ml, preferably 25 μ g/ml insulin; between 1 nM and 100 nM, preferably 30 nM sodium selenite; between 100 ng/ml and 500 μ g/ml, preferably 50 μ g/ml transferrin; between 100 ng/ml and 100 μ g/ml, preferably 5 μ g/ml fibronectin;

- 10 -

between 500 ng/ml and 100 µg/ml, preferably 1 µg laminin; between 10 µM and 500 µM, preferably 100 µM putrescine; between 1 nM and 1 µM preferably 20 nM progesterone; between 100 µM and 100 mM, preferably 10 mM nicotinamide.

5

In addition, extracellular matrix (ECM) proteins, such as laminin (between 0.5 and 100 µg/ml, preferably 1 µg/ml, SIGMA), or collagens, or complex mixtures of growth factors and ECM proteins of basal lamina (Matrigel R, Collaborative Research/Becton Dickinson, 1:3 dilution = stock solution, final concentration in cultures = 1: 10) are included to enhance the number of pancreatic cells as well as their differentiation status.

The term "terminal differentiation medium" means a suitable medium for terminal differentiation of insulin-producing cells. Examples of suitable culture media in practising the present invention are prepared with a base of Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2mM L-glutamine, 1:100 non-essential amino acids and 450 µM α -monothioglycerol (Sigma). In addition, such medium can contain between 1 nM and 100 µM, preferably 2 nM Activin A; between 1nM and 100 µM, preferably 1 nM betacellulin; between 1 ng/ml and 100 µg/ml, preferably 10 ng/ml Human Growth Factor (HGF); between 1nM and 100 µM, preferably 10 nM Niacinamid and between 1 ng/ml and 100 µg/ml, preferably 2 ng/ml Transforming Growth Factor 2beta (TGF 2beta).

25

The term "pancreatic gene" means a gene or its protein product that is involved and required for pancreas development, more preferably beta-cell differentiation. Examples of such genes are Pdx1 (GenBank accession number AH005712), Pax4 (GenBank accession numbers XM004974, NM006193), Pax6 (GenBank accession number M93650), ngn3 (GenBank accession numbers XM005744, NM020999, AJ133776), Nkx6.1 (GenBank accession number AH007313), Nkx6.2, Nkx2.2 (GenBank accession number AF019415), HB9 (GenBank accession numbers

- 11 -

XM049383, AF107457), BETA2/NeuroD (GenBank accession numbers NM002500, XM002573), Isl1 (GenBank accession number NM002202), HNF1-alpha, HNF1-beta (GenBank accession number X71346), and HNF3 (GenBank accession numbers AF176112, AF176111) of human or animal origin. Preferred genes are Pdx1, Pax4, Pax6, and ngn3. Especially preferred genes are Pdx1, Pax4, and Pax6. Each gene can be used individually or in combination.

The term "activating one or more pancreatic gene" means delivering and introducing said pancreatic genes or proteins into stem cells.

In a preferred embodiment, the cDNA of one or more pancreatic genes is placed under the control of a regulatory region allowing the initiation of transcription and introduced into a cell by transfection methods such as electroporation, lipofection, calcium phosphate mediated, DEAE dextrans, and the like. Such methods and system are well described in the art and do not require any undue experimentation; see, for example, Joyner, "Gene Targeting: A Practical Approach", Oxford University Press, New York, 1993; Mansouri "Gene Targeting by Homologous Recombination in Embryonic Stem Cell", Cell Biology: A Laboratory Handbook, second ed., Academic Press, 1998. Gene expression of pancreatic gene can be assured by constitutive promoters such as the Cytomegalovirus promoter/enhancer region or inducible promoters such as the tetracycline inducible system. Expression vectors can also contain a selection agent such as the neomycin, hygromycin or puromycin resistance genes. Making such gene expression vectors are well known in the art; see Sambrook *et al.*, "Molecular Cloning, A laboratory Manual" third ed., CSH Press, Cold Spring Harbor, 2000; Gossen and Bujard, (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551). DNA transfer can also be achieved using a viral delivery system such as retrovirus, adenovirus, adeno-associated virus and lentivirus vectors.

- 12 -

In a further preferred embodiment, protein products of pancreatic genes can be delivered directly to stem cells. For example, protein delivery can be achieved by polycationic liposomes (Sells *et al.* (1995) Biotechniques 19:72-76), Tat-mediated protein transduction (Fawell *et al.* (1993) Proc. 5 Natl. Acad. Sci. USA 91:664-668) and by fusing a protein to the cell permeable motif derived from the PreS2-domain of the hepatitis-B virus (Oess and Hildt (2000) Gene Ther. 7:750-758). Preparation, production and purification of such proteins from bacteria, yeast or eukaryotic cells are well known by persons skilled in the art.

10

An additional embodiment of the present invention relates to a method for aggregating stem cells, preferably ES and EG cells, to form embryoid bodies. Embryoid bodies can be generated by a hanging drop method. For example, between 400-800 ES cells, preferably 600, are cultured in drops 15 of 20 µl of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, L-glutamine, non-essential amino acids and α-monothioglycerol placed on the lids of petri dishes filled with phosphate-buffered saline (PBS). Embryoid bodies are cultured in hanging drops for 2 days at 37°C with 5% CO₂ and then transferred to bacteriological petri 20 dishes (Greiner, Germany) and incubated a further 3 days in suspension culture. After 5 days, embryoid bodies are plated onto gelatin-coated 24-well plates, petri dishes or other suitable culture container and cultured for an additional 15 to 35 days at 37°C with 5% CO₂. Embryoid bodies can 25 also be produced in spinner cultures. For example, adherent stem cells are enzymatically dissociated using 0,2% trypsin and 0,05% EDTA in PBS (Life Technologies) and seeded at a density of 10⁷ cell/ml in 250 ml siliconised spinner flasks (Life Technologies) containing 100 culture medium. After 24 hours, 150 ml culture medium is added to a final volume of 250. Spinner flasks are stirred at 20 rpm using a stirrer system (Integra Biosciences). 30 Such methods are well known in the art and can be scaled up for industrial production without undue experimentation.

In a further embodiment of the invention, embryoid bodies are plated unto petri dishes containing differentiation medium and allowed to differentiate into insulin-producing cells for periods of 15 to 50 days, preferably 20 to 25 days (depending on the cell lines used; R1 wild type cells need longer 5 differentiation for generating insulin or glucagon-positive cells than Pdx-1⁺ or Pax4⁺ cells). In the method of the invention a high proportion of insulin-producing cells is obtained. After a differentiation time of 15 days, the proportion of insulin-producing cells is preferably at least 20%, more preferably at least 40% and most preferably at least 50%.

10

The proportion of insulin-producing cells may further be increased by a selection of nestin-positive cells. This selection preferably comprises the transfer of embryoid bodies, e.g. obtained by the hanging drop method, to a suspension culture and subsequent plating and/or replating on a suitable 15 medium, e.g. a poly-L-ornithine/laminin coated plate. The nestin selection procedure may lead to a further increase in the proportion of insulin-producing cells, e.g. a proportion of 70% or more.

20

In a further embodiment of the invention, differentiated insulin-producing cells can be isolated and purified using a method for selecting insulin secreting cell clones from ES cells by transfecting cells with a plasmid allowing the expression of neomycin, hygromycin or puromycin resistance gene under the control of the regulatory region of the human insulin gene. Cells can also be sorted using Fluorescent Activated Cell Sorting (FACS) 25 after Hoechst 33342 dye staining (Goodell *et al.* (1996) J. Exp. Med. 183:1797-1806). Further modifications of the above-mentioned embodiment of the invention can easily be devised by the person skilled in the art, without undue experimentation from this disclosure.

30

An additional embodiment of the present invention relates to a method for treating diabetes wherein between 3000 and 100 000 equivalent differentiated insulin-producing cells per kilogram body weight would be

- 14 -

introduced into a diabetic patient intraportally via a percutaneous transhepatic approach using local anaesthesia. Such surgical techniques are well known in the art and can be applied without any undue experimentation, see Pyzdrowski et al, "Preserved insulin secretion and insulin independence in recipients of islet autografts" New England J. Medicine 327:220-226, 1992; Hering et al., "New protocol toward prevention of early human islet allograft failure" Transplantation Proc. 26:570-571, 1993; Shapiro et al., "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen", New England J. Medicine 343:230-238, 2000. Furthermore, encapsulation technology could also be used for the transplantation of differentiated insulin-producing cells as described by Lanza et al., "Encapsulated cell technology", Nature Biotech 14:1107-1111, 1996.

Further, the invention relates to a cell composition comprising differentiated stem cells exhibiting insulin production, e.g. an insulin-producing cell line obtainable by the method as described above. The insulin-producing cells may exhibit a stable or a transient expression of at least one gene involved in β -cell differentiation, particularly a gene as described above. The cells are preferably human cells which are derived from human stem cells. For therapeutic applications the generation of autologous human cells from adult stem cells of a patient is especially preferred.

The insulin-producing cells of the invention exhibit characteristics which closely resemble naturally occurring β -cells. Particularly, the ratio of insulin-producing cells versus glucagon-producing cells is high. After 15 days of differentiation, this ratio is preferably at least 2:1 and more preferably at least 5:1. Further, the cells of the invention are capable of a quick response to glucose. After addition of 27.7 mM glucose, the insulin production is enhanced by a factor of at least 2, preferably by a factor of

- 15 -

at least 3 in the cells of the invention. Further, the cells of the invention are capable of normalizing blood glucose levels after transplantation into mice.

5 The cell composition of the invention is preferably a pharmaceutical composition comprising the cells together with pharmacologically acceptable carriers, diluents and/or adjuvants. The pharmaceutical composition is preferably used for the treatment of diabetes. The administration is preferably by transplantation as described above.

10 In a further embodiment, the present invention allows the generation of cells for the identification and/or characterisation of compounds which stimulate beta-cell differentiation, insulin secretion or glucose response. This method is particularly suitable for in vivo testing for diagnostic 15 applications and drug development or screening. The compound of interest is added to differentiated and undifferentiated insulin-producing cells which are grown in appropriate culture system, for example 96 and 384 well plates. Insulin levels in treated cells can be quantified by Enzyme Linked Immunoabsorbent Assay (ELISA) or Radio Immuno Assay (RIA). Using this 20 method, a large number of compounds can be screened and compounds that induce beta-cell differentiation and increase insulin secretion can be identified readily.

Preferred embodiments for high-throughput screening and medium 25 throughput validation methods are described in Fig. 11. In a high-throughput screening method, the cells are transfected with a DNA construct, e.g. a viral or non-viral vector containing a reporter gene, e.g. the lacZ gene or the GFP gene, under regulatory control of a promoter of a gene involved in β -cell differentiation, e.g. a promoter of a gene as described above, preferably a Pax4 promoter. The transfected cells are divided into aliquots and each aliquot is contacted with a test substance, e.g. candidate 1, candidate 2 and candidate 3. The activity of the reporter 30

- 16 -

gene corresponds to the capability of the test compound to induce β -cell differentiation.

In a further embodiment (which may be combined with the high-throughput screening as described above) a medium throughput validation is carried out. Therein, the test compound is added to stem cells being cultivated and the insulin production is determined. Following an initial high throughput assay, such as the cell based assay outlined above where e.g. a Pax4 promoter is used as marker for beta-cell regeneration, the activity of candidate molecules to induce beta-cell differentiation is tested in a validation assay comprising adding said compounds to the culture media of the embryoid bodies. Differentiation into insulin-producing cells is then evaluated, e.g. by comparison to wild type and/or Pax4 expressing ES cells to assess the effectiveness of a compound.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Expression vectors containing the Pdx1, Pax4, Pax6, and ngn3 gene.

20

The Pdx1, Pax4, Pax6, and ngn3 (SEQ ID No. 1, 2, 3, 4) cDNA were inserted into the expression vector pACCMV.pLpA previously described by Becker *et al.* (Becker *et al.* (1994) *Meth. Cell Biol.* 43:161-189). Briefly, a Kpn I-Bam HI fragment that included the Pdx1 cDNA (SEQ ID No.1) was introduce into the KpnI-BamHI sites of pACCMV.pLpA, placing the Pdx1 gene under the control of the Cytomegalovirus (CMVp) promoter. Likewise, a Bam HI-Hind III fragment that include the Pax4 cDNA (SED ID No. 2) was introduce into the Bam HI-Hind III sites of pACCMV.pLpA, placing the Pax4 gene under the control of the CMV promoter; a Bam HI-Hind III fragment that includes the Pax6 cDNA (SED ID No.3) was introduced into the Bam HI-Hind III sites of pACCMV.pLpA, placing the Pax6 gene under the control of the CMV promoter; and a Bam HI-Xba I that includes the ngn3 cDNA

- 17 -

(SEQ ID No. 4) was introduced into the Bam HI-Xba I sites of pACCMV.pLpA, placing the ngn3 gene under the control of the CMV promoter. Abbreviations: B, Bam HI; H, Hind III; K, Kpn I; X, Xba I; Ad 5, adenovirus type 5.

5

Figure 2. Differentiation of ES cells into insulin-producing cells

Wild type and Pdx1 expressing embryonic stem (ES) cells were cultivated as embryoid bodies (EB; EBs) by the hanging drops method. Differentiation and terminal differentiation media are applied upon plating of EBs.

Figure 3. Amount of hormone-producing cells in Pdx1 + differentiated ES cells

15 Immunofluorescence observation of insulin, glucagon, pancreatic polypeptide (PP) and somatostatin-positive cells following plating of Pdx1 + embryoid bodies cultured in normal culture medium and differentiation medium. Results illustrated over time in arbitrary units representing the average number of hormone-producing cells in define areas of the culture dishes. The number of hormone-producing cells (i.e. insulin, glucagon, PP, and somatostatin) is higher when embryoid bodies are cultured in differentiation and terminal differentiation media.

20

Figure 4. Expression of pancreas specific genes after differentiation of wild type, Pdx1⁺, and Pax4⁺ ES cells into insulin-producing cells.

25 mRNA levels of pancreas specific genes following formation of embryoid bodies by the hanging drop method and plating in differentiation medium. Insulin and Glut2 levels are higher in Pdx1⁺ and Pax4⁺ ES cells than in wild type ES cells indicating that differentiation is more efficient when a pancreatic developmental control gene is activated.

- 18 -

Figure 5. Differentiation of mouse ES cells into insulin-producing cells.

The proportion of insulin-producing cells was determined in wild type cells (R1), and Pdx1 and Pax4 expressing cells, 5, 6, 10, and 15 days after plating.

Figure 6. Insulin-producing cells versus glucagon-producing cells.

The expression of insulin and glucagon in wild type ES cells, Pdx1 expressing cells and Pax4 expressing cells was determined 5, 10 or 15 days after plating.

Figure 7. Glucose response of Pax4 ES cell derived insulin cells.

The insulin secretion of wild type (R1) and Pax4 ES derived insulin-producing cells was determined in the absence of glucose and 15 minutes after stimulation with 27.7 mM glucose.

Figure 8. Regulation of blood glucose level in diabetic mice.

The blood glucose level of diabetic control mice (STZ control) and diabetic mice having received a transplant of insulin-producing cells derived from Pax4 ES cells was determined.

Figure 9. Drug screening strategies.

A high-throughput screening and a medium throughput validation method for three test compounds are shown. An initial high throughput screen is performed in a cell assay using Pax promoters as reporter for beta-cell differentiation. Positive candidates are then validated in a medium throughput assay involving embryoid bodies. Compounds are tested at

- 19 -

different stages of culture for their potential to induce the formation of insulin-producing cells.

5 **Figure 10.** Differentiation methods of ES cells into insulin-producing cells using culture conditions favouring the formation of nestin-positive cells.

Figure 11. Differentiation of nestin-positive mouse ES cells into insulin-producing cells.

10 **EXAMPLES**

A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.

15 **Example 1:** Generation of ES cells expressing the Pdx1 or Pax6 gene.

The mouse R1 ES cells (Nagy *et al.* (1993) Proc. Natl. Acad. Sci. U S A. 90:8424-8) were electroporated with the Pax6 or the Pdx1 gene under the control of the CMV promoter (see figure 1) and the neomycin resistance gene under the control of the phosphoglycerate kinase I promoter (pGK-1).
20 ES cells are cultured in Dulbecco's modified Eagle's medium (DMEM, Life Technologies) containing 4.5 g/l glucose, 10⁻⁴ M beta-Mercaptoethanol, 2nM glutamine, 1% non essential amino acids, 1 nM Na-pyruvate, 15% FCS and 500 U/ml leukaemia inhibitory factor (LIF). Briefly, approximately
25 10⁷ ES cells resuspended in 0.8 ml phosphate buffered saline (PBS) containing 25 µg/ml of linearized expression vector and electroporated with one pulse of 500 µF and 250 volts at room temperature using a Gene Pulser electroporation apparatus (BioRad). Five minutes after electroporation, ES cells are plated on 8.5 cm petri dishes containing
30 fibroblastic feeder cells previously inactivated by treatment with 100 µg/ml mitomycin C for 3 hours. One day after electroporation, culture medium is

- 20 -

changed to medium containing 450 µg/ml G418. Resistant clones are separately isolated and cultured 14 days after applying the selection medium. Cells are always cultured at 37°C, 5% CO₂.

5 **Example 2: Differentiation of ES cells into insulin-producing cells.**

The ES cell line R1 (wild type, wt) and ES cells constitutively expressing Pdx1 (Pdx1+) were cultivated as embryoid bodies (EB; EBs) by the hanging drops method (Figure 2). Briefly, approximately 600 cells were 10 placed in drops of 20 µl medium composed of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, L-glutamine, non-essential amino acids and alpha-monothioglycerol (Sigma, Steinheim, Germany; final concentration 450 µM). Drops were placed on the lids of petri dishes filled with phosphate-buffered saline (PBS). The EBs were 15 allowed to form in hanging drops cultures for 2 days and then transferred for three days to suspension cultures in bacteriological petri dishes (Greiner, Germany). At day 5, EBs were plated separately onto gelatin-coated 24-well plates containing a differentiation medium prepared with a base of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented 20 with 20% FCS, 2mM L-glutamine, 1:100 non-essential amino acids, 450 µM α-monothioglycerol (Sigma), 10 ng/ml Epithelial Growth Factor (EGF, R&D Research), 2 ng/ml basic Fibroblast Growth Factor (bFGF, R&D Research), 20 nM progesterone (R&D Research), 100 ng/ml Human Growth Hormone (HGH, R&D Systems) and 5 nM follistatin (R&D Systems) and/or 25 2nM human activin A (R& D Systems). Cells were cultured for 15 to 40 days in the differentiation medium. To enhance differentiation capacity, a terminal differentiation medium can be applied at stages between 5 and 20 days after EB plating.

Example 3. Hormonal expression in differentiated ES cells.

Expression of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) was verified by immunofluorescence in differentiated wt and Pdx1+ ES cells. Immunofluorescence was performed according to standard protocols (see Wobus *et al.*: In Vitro Differentiation of Embryonic Stem Cells and Analysis of Cellular Phenotypes, In: Tymms, M.J. and Kola, I. (Eds.) Gene Knockout Protocols, vol. 158, Methods in Molecular Biology, Humana Press, Totowa, New Jersey, 2001). Briefly, differentiated wt or Pdx1+ ES cells are grown on cover slips and rinsed twice with PBS and fixed with methanol: acetone 7:3 at -20°C for 10 min. The following antibodies were used: Mouse anti-insulin (Sigma-Aldrich Co.), rabbit anti-glucagon (Dako Corporation), rabbit anti-somatostatin (Dako Corporation), rabbit anti-PP (Dako Corporation) were used as primary antibody while Fluorescein (DTAF)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and Cy^{3TM}-conjugated goat anti rabbit IgG (Jackson ImmunoResearch Laboratories) were used as second antibody. In this study double immunostaining was performed, and the following pairs of antibodies were used: anti-insulin and anti-glucagon; anti-insulin and anti-somatostatin; anti-insulin and anti-PP. Cells were analyzed with a fluorescence microscope Optiphot-2 (Nikon) and a confocal laser scanning microscope (CLSM) LSM-410 (Carl Zeiss). Differentiated wt ES cells co-express insulin, glucagon, PP, and somatostatin indicating that the cells have not undergone maturation into single hormone-producing cells. However, differentiated Pdx1+ cells separately express either insulin or glucagon but, rarely both hormones at the same cells demonstrating that such cells achieve maturation into single hormone-producing cells. The number of hormone-producing cell is higher when Pdx1+ ES cells are cultured in a differentiation medium (see Fig.3) illustrating that differentiation into insulin-producing cells is more efficient when a pancreatic developmental control gene is expressed in a stem cell (e.g. ES) and when such cells are cultured in a differentiation medium.

- 22 -

Example 4: Expression of pancreas specific genes after differentiation of ES cells into insulin-producing cells.

Expression levels of pancreas specific genes was measured by semi-
5 quantitative RT-PCR analysis. Differentiated wild type, Pdx-1⁺ and Pax4⁺ cells have been collected after embryoid body formation (5d) and 2, 7, 10,
10 15, 21 and 24 days after plating (5 + 2d, + 7d, + 10d, + 15d, + 21d, +
24d) were suspended in lysis buffer (4 M guanidinium thiocyanate, 25 mM
sodium citrate, pH 7; 0.5% sarcosyl, 0.1 M beta-mercaptoethanol). Total
15 RNA was isolated by the single step extraction method described by
Chomczynski and Sacchi (Chomczynski and Sacchi (1987) Anal. Biochem.
162: 156-159). mRNA was reverse transcribed using PolyT tail primer
Oligo d(T)₁₆ (PerkinElmer) and the resulting cDNA was amplified using
oligonucleotide primers complementary and identical to transcripts of the
15 following genes: GLUT2 (SEQ ID No 9 and 10; annealing temperature
60°C for 40 cycles, expected fragment size 556 bp), insulin (SEQ ID No
11 and 12; annealing temperature: 60°C for 40 cycles, expected fragment
size 340 bp), ngn-3 (SEQ ID No 13 and 14; annealing temperature: 60°C
for 40 cycles, expected fragment size 514 bp), Pdx-1 (SEQ ID No 15 and
20 16; annealing temperature: 60°C for 45 cycles, expected fragment size
230 bp) and Isl1 (SEQ ID No 17 and 18; annealing temperature: 60°C for
40 cycles, expected fragment size 514 bp). The house keeping gene beta-
25 tubulin (SEQ ID No 19 and 20, annealing temperature: 60°C for 28 cycles,
expected fragment size 317 bp) was used as internal standard. Reverse
transcription (RT) was performed with MuLV reverse transcriptase (Perkin
Elmer). Multiplex PCRs were carried out using AmpliTaq DNA polymerase
(Perkin Elmer) as described in Wobus at al., 1997. Briefly, RT reactions (20
μl) were performed with MuLV reverse transcriptase. Separate PCRs using
primers of the analysed genes or primers of the house keeping gene beta-
30 tubulin were carried out with 3 μl of the RT products.

- 23 -

mRNA levels of genes encoding Pax4 and insulin were analysed using the Dynalbeads mRNA DIRECT micro kit (Dynal) according to the manufacturer's instructions.

- 5 One third of each PCR reaction was separated by electrophoresis on 2% agarose gels containing 0.35 µg/ml of ethidium bromide. Gels were illuminated with UV light and the ethidium bromide fluorescence signals of gels were stored by the E.A.S.Y. system (Herolab) and analyzed by the TINA2.08e software (Raytest Isotopenmeßgeräte GmbH). The intensity of
10 the ethidium bromide fluorescence signals was determined from the area under the curve for each peak and the data of target genes were plotted as percentage changes in relation to the expression of the housekeeping gene beta-tubulin.
- 15 Results show that markers for beta-cell differentiation function were expressed at higher levels in Pdx1⁺ and Pax4⁺ differentiated ES cells than in differentiated wild type ES cells demonstrating that activation of a pancreatic developmental control gene renders differentiation more efficient than for wild type ES cells (Figure 4). Expression of GLUT2 in differentiated stem cells indicates that hormone-producing cells are capable of responding to glucose. In addition, genes involved in early endodermal/pancreatic precursor cell specification such as ngn3 and Isl1
20 are downregulated in Pdx-1⁺ and Pax4⁺ ES cells, consistent with *in vivo* data indicating that such cells have matured into single hormone-producing cells.
25

Example 5: Hormonal expression of differentiated ES cells expressing Pdx1 and Pax4

- 30 In order to study the potential of pancreatic developmental control to induce beta-cell differentiation *in vitro*, we have generated stable mouse embryonic stem (ES) cells expressing the Pax4 or Pdx1 gene under the

- 24 -

control of the cytomegalovirus (CMV) early promoter/enhancer region (see Figure 1a,b). The CMV-Pax4 and CMV-Pdx1 transgenes were introduced into ES cells by electroporation, a method that is well known in the art, for example see Joyner, "Gene Targeting: A Practical Approach", Oxford University Press, New York, 1993; Mansouri "Gene Targeting by Homologous Recombination in Embryonic Stem Cell", Cell Biology: A Laboratory Handbook, second ed., Academic Press, 1998. Pax4, Pdx1 and wild type ES cells were then cultured in hanging drops or spinner cultures to allow the formation of embryoid bodies. Embryoid bodies were subsequently plated and cultured in a differentiation medium containing various growth factors. Under such conditions, insulin-producing cells can be detected in Pdx1 and Pax4 expressing cells six days after plating (Figure 5). By comparison, wild type ES cells did not contain any insulin-producing cell at the same stage. Ten days after plating, 12% of Pdx1 and Pax4 expressing cells were positive for insulin while the first insulin-producing cells are observed in wild type ES cells. At day 15 of plating, up to 60% of the Pax4 ES cells are positive for insulin compared to 22% for Pdx1 ES cells and 6% for wild type ES cells. These data demonstrate that Pax4, and to some extent Pdx1, can significantly promote, and enhance ES cells differentiation into insulin-producing cells compared to wild type ES cells.

The expression of Pax4 also affects the differentiation status of the insulin-producing cell. During embryogenesis, the first hormone-producing cells to arise in the developing pancreas co-express both insulin and glucagon. These cells subsequently differentiate and mature into single hormone-producing cells. In a similar fashion, all insulin-producing cells obtained from wild type ES cells also co-express glucagon suggesting that differentiation of the cells is arrested at a premature stage (Figure 6). Such cells most likely have little therapeutic value since insulin and glucagon have opposing effect on blood glucose levels in an organism. However in Pax4 ES cells, single insulin-producing cells are generated in substantial amounts (Figure 6). Insulin-glucagon co-expressing cells are detected in

small numbers and most likely represent an ongoing differentiation process within the cultures. This observation demonstrate that Pax4 induces, and enhances the differentiation of insulin-producing cells which are more mature than the cells observed in wild type ES cells.

5

Example 6: Functional characterisation of the differentiated insulin-producing cells.

One important property of beta-cells is glucose responsive insulin secretion. To test whether the Pax4 derived insulin-producing cells possessed this glucose responsive property, in vitro glucose responsive assay was performed on the differentiated cells. Briefly, between 10 and 14 embryoid bodies were cultured in 3 cm petri dishes containing the above mentioned differentiation medium. On the day of the assay, the differentiation medium was removed and the cells were washed 3 times with Krebs Ringer Bicarbonate Hepes Buffer (KRBH; 118 mM NaCl, 4.7 KCl, 2.5 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 24.6 NaHCO₃, 10 mM Hepes, 2 mg/ml BSA). Cells were then incubated in 750 µl KRBH for 45 minutes at 37°C. The KRBH was then kept for measurement of basal insulin secretion and 750 µl KRBH containing 27.7 mM glucose was added to the cells. After 15 minutes incubation at 37°C, the KRBH was removed from the cells for measurement of glucose induce insulin secretion. Insulin levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) for mouse insulin (Mercodia) and performed according to the manufacturer's recommendations. An alternative medium for proper insulin release is medium based on DMEM with glucose concentration of 1 g/l (Gibco) supplemented with non-essential amino acids (Gibco, stock solution 1:100) and additional factors mentioned above. Such medium can be applied 1 to 6 days before use of the cells.

20

A basal insulin secretion is observed when both wild type and Pax4 ES derived insulin-producing cells are cultured in the absence of glucose

25

- 26 -

(Figure 7). However, only the Pax4 ES derived insulin-producing cells respond to glucose stimulation. In the presence of glucose, a five fold increase in insulin secretion is seen in Pax4 ES derived insulin-producing cells. Wild type ES derived insulin-producing cells do not respond to glucose.

Example 7: Transplantation of Pax4 ES derived insulin-producing cells in STZ diabetic mice.

The therapeutic potential of Pax4 ES derived insulin-producing cells to improve and cure diabetes was investigated by transplanting the cells into streptozotocin induced diabetic mice. Streptozotocin is an antibiotic which is cytotoxic to beta-cells when administered at certain dosage (see Rodrigues et al.: Streptozotocin-induced diabetes, in McNeill (ed) Experimental Models of Diabetes, CRC Press LLC, 1999). Its effect is rapid, rendering an animal severely diabetic within 48 hours.

Non-fasted Male BalbC mice were treated with 170 mg/Kg body weight STZ. Under such conditions, 17 control mice developed hyperglycaemia 6 days after STZ treatment. Mice are considered diabetic if they have a blood glucose level above 10 mMol/l for more than 3 consecutive days. One mouse did not respond to the STZ treatment. Elevated blood glucose levels varied significantly between animals and between days. This is indicative of diabetes since the animals cannot regulate their blood glucose. Cells were transplanted under the kidney capsule and into the spleen of animals. Briefly, mice were anaesthetised by intraperitoneal injection of 15 µl/g body weight avertin (2,5% tribromoethyl alcohol:tertiary amyl alcohol). The kidney and the spleen was exposed through a lumbar incision, and cells were transferred into each tissue using a blunt 30G needle.

Transplantation of cells under the kidney capsule and into the spleen were performed 24-48 hours after STZ treatment. 8 animals were transplanted

- 27 -

with between 1×10^6 and 5×10^6 Pax4 ES derived insulin-producing cells. 4 out of 8 transplanted animals died due to the surgical procedure. Of the 4 animals that did survived, none developed diabetes when compared with STZ-treated control animals (Figure 8). The presence of the insulin-producing cells was confirmed by immunohistological analysis of the transplanted tissue. These results demonstrate that the transplanted cells can normalise blood glucose in diabetic animals.

10 **Example 8:** Differentiation of ES cells into insulin-producing cells using culture conditions favouring the formation of nestin-positive cells.

For differentiation of nestin-positive cells, mouse ES cells were cultivated for 2 days in hanging drops (100, 200, or 400 cells/drop) to form embryoid bodies (EBs; Figure 10). EBs were then transferred to bacteriological petri dishes (Greiner, Germany) and cultivated for additional 2 days in Iscove's modification of DMEM (IMDM; Gibco) containing 20% FCS and supplements as described (Rohwedel et al., 1998), Dev. Biol. 201(2):167-184), with the exception that beta-mercaptoethanol was replaced by 450 mM alpha-monothioglycerol (Sigma, Steinheim, Germany). Between 20 and 20 30 EBs were plated onto tissue culture dishes (diameter 6 cm) at day 4, and cultivated in IMDM supplemented with 20% FCS for 24 hours. The selection of nestin-positive cells was carried out according to the method described by Okabe and colleagues (Okabe et al., 1996, Mech. Dev. 59:89-102) with the following modifications: After attachment of EBs (day 25 4+1), the medium was exchanged for a B1 medium prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies) supplemented with 5 mg/ml insulin, 30 nM sodium selenite (both from Sigma), 50 mg/ml transferrin, and 5 mg/ml fibronectin (both from Gibco). The B1 culture medium was replenished 30 every 48 hours. Nestin-positive cells were selected after cultivation for 7 days (= 4+7d). At day 4+8, EBs were dissociated with 0.1% trypsin (Gibco)/0.08% EDTA (Sigma) in phosphate buffered saline (PBS) (1:1) for

- 28 -

1 min, collected by centrifugation, and replated onto poly-L-ornithine/laminin-coated tissue culture dishes containing a B2 medium prepared with a base DMEM/F12 supplemented with 10% FCS; 20 nM progesterone; 100 mM putrescine; 1 mg/ml laminin (all from Sigma); 25 mg/ml insulin; 50 mg/ml transferrin; 30 nM sodium selenite; B27 supplement; and 10 mM nicotinamide. This medium was replaced after 24 hours with B2 medium lacking FCS. At day 30 of plating; >75% of the Pax4 ES cells are positive for insulin compared to 20% for wild type ES cells (Figure 11).

10

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

15

20

Claims

1. A method for differentiating stem cells into insulin-producing cells
5 comprising:
culturing stem cells in a suitable medium and activating at least one gene involved in beta-cell differentiation.
2. The method of claim 1 further comprising:
10 aggregating said cultivated stem cells to form embryoid bodies, cultivating said embryoid bodies in a differentiation medium enhancing β -cell differentiation, identifying, and optionally selecting insulin-producing cells.
- 15 3. The method of claim 1 or 2, wherein said stem cells are selected from embryonic stem cells, adult stem cells, somatic stem cells and primordial germ cells.
- 20 4. The method of any one of claims 1-3, wherein said stem cells are of human origin.
- 25 5. The method of any one of claims 1-4, wherein the genes involved in β -cell differentiation are selected from the group consisting of Pdx1, Pax4, Pax6, ngn3, Nkx6.1, Nkx6.2, Nkx2.2, HB9, BETA2, NeuroD, Isl1, HNF1-alpha, HNF1-beta, HNF3, and combinations thereof.
6. The method of claim 5, wherein the genes are selected from Pdx1, Pax4, Pax6, ngn3, and combinations thereof.
- 30 7. The method of claim 5 or 6, wherein the genes are of human origin.

- 30 -

8. The method of any one of claims 1-7, wherein the gene activation comprises a delivery of a pancreatic gene into stem cells.
9. The method of claim 8, wherein said gene delivery comprises a transfection of stem cells with a cDNA of at least one pancreatic gene under the control of a regulatory region allowing the initiation of transcription.
5
10. The method of claim 8, wherein said gene delivery comprises a DNA transfer using a viral delivery system.
10
11. The method of any one of claims 1-7, wherein the gene activation comprises a delivery of a protein product of a pancreatic gene into stem cells.
15
12. The method of any one of claims 2-11, wherein said embryoid bodies are formed by a hanging drop method.
13. The method of any one of claims 2-12, wherein said differentiation medium is based on Iscove's modified Dulbecco's medium (IMDM) supplemented with fetal calf serum, L-glutamine, non-essential amino acids, and α -monothioglycerol optionally containing EGF, bFGF, progesterone, growth hormone, follistatin, and/or activin.
20
14. The method of claim 13, wherein said differentiation medium further contains extracellular matrix proteins, collagens, and/or mixtures of growth factors and extracellular matrix proteins.
25
15. The method of any one of claims 1-14, wherein at least 20% insulin-producing cells are obtained after a differentiation time of 15 days.
30

- 31 -

16. The method of claim 15, wherein at least 40% insulin-producing cells are obtained.
- 5 17. The method of any one of claims 1-16 further comprising a selection of nestin-positive cells.
- 10 18. The method of any one of claims 1-17, wherein the insulin-producing cells are used for pharmaceutical applications.
- 15 19. The method of claim 18 for the treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, such as diabetes, hyperglycaemia, and/or impaired glucose tolerance.
20. 20. The method of claim 18 or 19, wherein between 3000 and 100000 equivalent differentiated insulin-producing cells are administered per kilogram body weight.
- 25 21. A cell composition comprising insulin-producing cells obtainable by the method of any one of claims 1-17.
22. The composition of claim 21 comprising at least 20% insulin-producing cells after a differentiation time of 15 days.
- 25 23. The composition of claim 22 comprising at least 40% insulin-producing cells.
- 30 24. The composition of any one of claims 21-23 comprising a ratio of insulin-producing cells versus glucagon-producing cells of at least 2:1.
25. The composition of claim 24 comprising a ratio of at least 5:1.

- 32 -

26. The composition of any one of claims 21-25 exhibiting an increase in the insulin secretion of at least 2-fold 15 min after stimulation with 27.7 mM glucose.
- 5 27. The composition of any one of claims 21-26, which is a pharmaceutical composition.
- 10 28. The composition of claim 27 for the treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, such as diabetes, hyperglycaemia, and/or impaired glucose tolerance.
- 15 29. The composition of claim 27 or 28, which is administered by transplantation or used in a medical device.
- 20 30. A method for identifying and/or characterizing compounds capable of modulating the differentiation of stem cells into insulin-producing cells comprising:
contacting a compound to be tested with stem cells under conditions wherein the stem cells are capable of being differentiated into insulin-producing cells and determining the effect of the compound on the differentiation process.
- 25 31. The method of claim 30 comprising transfecting stem cells with a DNA construct containing a reporter gene under regulatory control of a gene involved in β -cell differentiation, contacting said transfected cells with a compound to be tested and determining the activity of the reporter gene.
- 30 32. The method of claim 30 or 31 comprising contacting embryoid bodies which are cultivated in a differentiation medium enhancing β -

- 33 -

cell differentiation with a compound to be tested and determining differentiation into insulin-producing cells.




Figure 1




Figure 2




Figure 3

Analysis of mRNA level of genes involved in pancreatic β cell development in differentiating wt, Pdx-1 $^+$, and Pax4 $^+$ ES cells




Figure 4

5/11




Figure 5

Insulin-producing cells vs. glucagon-producing cells




Figure 6

Pax4 ES-cell derived insulin cells respond to glucose




Figure 7

8/11







Figure 8

Drug screening strategy

High throughput screening



Medium throughput validation






Figure 10

11/11




Figure 11

SEQUENCE LISTING

<110> DeveloGen A.G.

<120> A Method For Differentiating Stem Cells Into
Insulin-Producing Cells

<130> Insulin-ES cells

<140>

<141>

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 1122

<212> DNA

62132 Mus musculus

53303

52213 CPS

5222 (54) (905)

<400> 1

cctggcttgt agctccgacc cggggctgtct ggccccaaagt gccggctgcc acc atg 56
Met
1

```

aac agt gag gag cag tac tac gcg gcc aca cag ctc tac aag gac ccg 104
Asn Ser Glu Glu Gln Tyr Tyr Ala Ala Thr Gln Leu Tyr Lys Asp Pro
      5           10          15

```

tgc gca ttc cag agg ggc ccg gtg cca gag ttc agc gct aac ccc cct 152
 Cys Ala Phe Gln Arg Gly Pro Val Pro Glu Phe Ser Ala Asn Pro Pro
 20 25 30

gct tgc ctg tac atg ggc cgc cag ccc cca cct ccg ccg cca ccc cag 200
 Ala Cys Leu Tyr Met Gly Arg Gln Pro Pro Pro Pro Pro Pro Pro Gln
 35 40 45

ttt aca agc tcg ctg gga tca ctg gag cag gga agt cct ccg gac atc 248
 Phe Thr Ser Ser Leu Gly Ser Leu Glu Gln Gly Ser Pro Pro Asp Ile
 50 55 60 65

tcc cca tac gaa gtg ccc ccg ctc gcc tcc gac gac ccg gct ggc gct 296
Ser Pro Tyr Glu Val Pro Pro Leu Ala Ser Asp Asp Pro Ala Gly Ala

70	75	80	
cac ctc cac cac ctt cca gct cag ctc ggg ctc gcc cat cca cct His Leu His His His Leu Pro Ala Gln Leu Gly Leu Ala His Pro Pro			344
85	90	95	
ccc gga cct ttc ccg aat gga acc gag cct ggg ggc ctg gaa gag ccc Pro Gly Pro Phe Pro Asn Gly Thr Glu Pro Gly Gly Leu Glu Glu Pro			392
100	105	110	
aac cgc gtc cag ctc cct ttc ccg tgg atg aaa tcc acc aaa gct cac Asn Arg Val Gln Leu Pro Phe Pro Trp Met Lys Ser Thr Lys Ala His			440
115	120	125	
gcg tgg aaa ggc cag tgg gca gga ggt gct tac aca gca gaa ccc gag Ala Trp Lys Gly Gln Trp Ala Gly Gly Ala Tyr Thr Ala Glu Pro Glu			488
130	135	140	145
gaa aac aag agg acc cgt act gcc tac acc cgg gcg cag ctg ctg gag Glu Asn Lys Arg Thr Arg Thr Ala Tyr Thr Arg Ala Gln Leu Leu Glu			536
150	155	160	
ctg gag aag gaa ttc tta ttt aac aaa tac atc tcc cgg ccc cgc cgg Leu Glu Lys Glu Phe Leu Phe Asn Lys Tyr Ile Ser Arg Pro Arg Arg			584
165	170	175	
gtg gag ctg gca gtg atg ttg aac ttg acc gag aga cac atc aaa atc Val Glu Leu Ala Val Met Leu Asn Leu Thr Glu Arg His Ile Lys Ile			632
180	185	190	
tgg ttc caa aac cgt cgc atg aag tgg aaa aaa gag gaa gat aag aaa Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys Glu Glu Asp Lys Lys			680
195	200	205	
cgt agt agc ggg acc ccg agt ggg ggc ggt ggg ggc gaa gag ccg gag Arg Ser Ser Gly Thr Pro Ser Gly Gly Gly Glu Glu Pro Glu			728
210	215	220	225
caa gat tgt gcg gtg acc tcg ggc gag gag ctg ctg gca gtg cca ccg Gln Asp Cys Ala Val Thr Ser Gly Glu Leu Leu Ala Val Pro Pro			776
230	235	240	
ctg cca cct ccc gga ggt gcc gtg ccc cca ggc gtc cca gct gca gtc Leu Pro Pro Pro Gly Gly Ala Val Pro Pro Gly Val Pro Ala Ala Val			824
245	250	255	
cgg gag ggc cta ctg cct tcg ggc ctt agc gtg tcg cca cag ccc tcc Arg Glu Gly Leu Leu Pro Ser Gly Leu Ser Val Ser Pro Gln Pro Ser			872

260

265

270

agc atc gcg cca ctg cga ccg cag gaa ccc cgg tgaggacagc agtctgaggg 925
 Ser Ile Ala Pro Leu Arg Pro Gln Glu Pro Arg

275

280

tgagcggtc tgggacccag agtgtggacg tgggagcggs cagctggata agggaaactta 985

accttaggcgt cgcacaagaa gaaaattctt gagggcacga gagccagttg gatagccgga 1045

gagatgctgc gagcttctgg aaaaacagcc ctgagcttct gaaaactttg aggctgcttc 1105

tgatccaag ctaatgg 1122

<210> 2

<211> 284

<212> PRT

<213> Mus musculus

<400> 2

Met Asn Ser Glu Glu Gln Tyr Tyr Ala Ala Thr Gln Leu Tyr Lys Asp			
1	5	10	15

Pro Cys Ala Phe Gln Arg Gly Pro Val Pro Glu Phe Ser Ala Asn Pro			
20	25	30	

Pro Ala Cys Leu Tyr Met Gly Arg Gln Pro Pro Pro Pro Pro Pro			
35	40	45	

Gln Phe Thr Ser Ser Leu Gly Ser Leu Glu Gln Gly Ser Pro Pro Asp			
50	55	60	

Ile Ser Pro Tyr Glu Val Pro Pro Leu Ala Ser Asp Asp Pro Ala Gly			
65	70	75	80

Ala His Leu His His Leu Pro Ala Gln Leu Gly Leu Ala His Pro			
85	90	95	

Pro Pro Gly Pro Phe Pro Asn Gly Thr Glu Pro Gly Gly Leu Glu Glu			
100	105	110	

Pro Asn Arg Val Gln Leu Pro Phe Pro Trp Met Lys Ser Thr Lys Ala			
115	120	125	

His Ala Trp Lys Gly Gln Trp Ala Gly Gly Ala Tyr Thr Ala Glu Pro			
130	135	140	

Glu Glu Asn Lys Arg Thr Arg Thr Ala Tyr Thr Arg Ala Gln Leu Leu
 145 150 155 160

Glu Leu Glu Lys Glu Phe Leu Phe Asn Lys Tyr Ile Ser Arg Pro Arg
 165 170 175

Arg Val Glu Leu Ala Val Met Leu Asn Leu Thr Glu Arg His Ile Lys
 180 185 190

Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys Glu Glu Asp Lys
 195 200 205

Lys Arg Ser Ser Gly Thr Pro Ser Gly Gly Gly Gly Glu Glu Pro
 210 215 220

Glu Gln Asp Cys Ala Val Thr Ser Gly Glu Glu Leu Leu Ala Val Pro
 225 230 235 240

Pro Leu Pro Pro Pro Gly Gly Ala Val Pro Pro Gly Val Pro Ala Ala
 245 250 255

Val Arg Glu Gly Leu Leu Pro Ser Gly Leu Ser Val Ser Pro Gln Pro
 260 265 270

Ser Ser Ile Ala Pro Leu Arg Pro Gln Glu Pro Arg
 275 280

<210> 3
 <211> 1084
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (24)...(1019)

<400> 3
 tgcgaggagt accagtgtga agc atg cag cag gac gga ctc agc agt gtg aat 53
 Met Gln Gln Asp Gly Leu Ser Ser Val Asn
 1 5 10

cag cta ggg gga ctc ttt gtg aat ggc cgg ccc ctt cct ctg gac acc 101
 Gln Leu Gly Gly Leu Phe Val Asn Gly Arg Pro Leu Pro Leu Asp Thr
 15 20 25

agg cag cag att gtg cag cta gca ata aga ggg atg cga ccc tgt gac 149

Arg Gln Gln Ile Val Gln Leu Ala Ile Arg Gly Met Arg Pro Cys Asp			
30	35	40	
att tca cgg agc ctt aag gta tct aat ggc tgt gtg agc aag atc cta 197			
Ile Ser Arg Ser Leu Lys Val Ser Asn Gly Cys Val Ser Lys Ile Leu			
45	50	55	
gga cgc tac tac cgc aca ggt gtc ttg gaa ccc aag tgt att ggg gga 245			
Gly Arg Tyr Tyr Arg Thr Gly Val Leu Glu Pro Lys Cys Ile Gly Gly			
60	65	70	
agc aaa cca cgt ctg gcc aca cct gct gtg gtg gct cga att gcc cag 293			
Ser Lys Pro Arg Leu Ala Thr Pro Ala Val Val Ala Arg Ile Ala Gln			
75	80	85	90
cta aag gat gag tac cct gct ctt ttt gcc tgg gag atc caa cac cag 341			
Leu Lys Asp Glu Tyr Pro Ala Leu Phe Ala Trp Glu Ile Gln His Gln			
95	100	105	
ctt tgc act gaa ggg ctt tgt acc cag gac aag gct ccc agt gtg tcc 389			
Leu Cys Thr Glu Gly Leu Cys Thr Gln Asp Lys Ala Pro Ser Val Ser			
110	115	120	
tct atc aat cga gta ctt cgg gca ctt cag gaa gac cag agc ttg cac 437			
Ser Ile Asn Arg Val Leu Arg Ala Leu Gln Glu Asp Gln Ser Leu His			
125	130	135	
tgg actcaa ctc aga tca cca gct gtg ttg gct cca gtt ctt ccc agt 485			
Trp Thr Gln Leu Arg Ser Pro Ala Val Leu Ala Pro Val Leu Pro Ser			
140	145	150	
ccc cac agt aac tgt ggg gct ccc cga ggc ccc cac cca gga acc agc 533			
Pro His Ser Asn Cys Gly Ala Pro Arg Gly Pro His Pro Gly Thr Ser			
155	160	165	170
cac agg aat cgg gct atc ttc tcc ccg gga caa gcc gag gca ctg gag 581			
His Arg Asn Arg Ala Ile Phe Ser Pro Gly Gln Ala Glu Ala Leu Glu			
175	180	185	
aaa gag ttt cag cgt ggg cag tat cca gat tca gtg gcc cgt ggg aag 629			
Lys Glu Phe Gln Arg Gly Gln Tyr Pro Asp Ser Val Ala Arg Gly Lys			
190	195	200	
ctg gct gcc acc tct cgt cct gaa gac acg gtg agg gtt tgg ttt 677			
Leu Ala Ala Ala Thr Ser Leu Pro Glu Asp Thr Val Arg Val Trp Phe			
205	210	215	
tct aac aga aga gcc aaa tgg cgc agg caa gag aag ctg aaa tgg gaa 725			

Ser Asn Arg Arg Ala Lys Trp Arg Arg Gln Glu Lys Leu Lys Trp Glu			
220	225	230	
gca cag ctg cca ggt gct tcc cag gac ctg acg ata cca aaa aat tct			773
Ala Gln Leu Pro Gly Ala Ser Gln Asp Leu Thr Ile Pro Lys Asn Ser			
235	240	245	250
cca ggg atc atc tct gca cag cag tcc ccc ggc agt gta ccc tca gct			821
Pro Gly Ile Ile Ser Ala Gln Gln Ser Pro Gly Ser Val Pro Ser Ala			
255	260	265	
gcc ttg cct gtg ctg gaa cca ttg agt cct tcc ttc tgt cag cta tgc			869
Ala Leu Pro Val Leu Glu Pro Leu Ser Pro Ser Phe Cys Gln Leu Cys			
270	275	280	
tgt ggg aca gca cca ggc aga tgt tcc agt gac acc tca tcc cag gcc			917
Cys Gly Thr Ala Pro Gly Arg Cys Ser Ser Asp Thr Ser Ser Gln Ala			
285	290	295	
tat ctc caa ccc tac tgg gac tgc caa tcc ctc ctt cct gtg gct tcc			965
Tyr Leu Gln Pro Tyr Trp Asp Cys Gln Ser Leu Leu Pro Val Ala Ser			
300	305	310	
tcc tca tat gtg gaa ttt gcc tgc cct gcc tca cca ccc atc ctg tgc			1013
Ser Ser Tyr Val Glu Phe Ala Cys Pro Ala Ser Pro Pro Ile Leu Cys			
315	320	325	330
atc atc tgattggagg cccaggacaa gtgccatcat cccattgctc aaactggcca			1069
Ile Ile			
taaccgcgga attcc			1084

<210> 4
<211> 332
<212> PRT
<213> Mus musculus

<400> 4
Met Gln Gln Asp Gly Leu Ser Ser Val Asn Gln Leu Gly Gly Leu Phe
1 5 10 15

Val Asn Gly Arg Pro Leu Pro Leu Asp Thr Arg Gln Gln Ile Val Gln
20 25 30

Leu Ala Ile Arg Gly Met Arg Pro Cys Asp Ile Ser Arg Ser Leu Lys
35 40 45

Val Ser Asn Gly Cys Val Ser Lys Ile Leu Gly Arg Tyr Tyr Arg Thr
 50 55 60
 Gly Val Leu Glu Pro Lys Cys Ile Gly Gly Ser Lys Pro Arg Leu Ala
 65 70 75 80
 Thr Pro Ala Val Val Ala Arg Ile Ala Gln Leu Lys Asp Glu Tyr Pro
 85 90 95
 Ala Leu Phe Ala Trp Glu Ile Gln His Gln Leu Cys Thr Glu Gly Leu
 100 105 110
 Cys Thr Gln Asp Lys Ala Pro Ser Val Ser Ser Ile Asn Arg Val Leu
 115 120 125
 Arg Ala Leu Gln Glu Asp Gln Ser Leu His Trp Thr Gln Leu Arg Ser
 130 135 140
 Pro Ala Val Leu Ala Pro Val Leu Pro Ser Pro His Ser Asn Cys Gly
 145 150 155 160
 Ala Pro Arg Gly Pro His Pro Gly Thr Ser His Arg Asn Arg Ala Ile
 165 170 175
 Phe Ser Pro Gly Gln Ala Glu Ala Leu Glu Lys Glu Phe Gln Arg Gly
 180 185 190
 Gln Tyr Pro Asp Ser Val Ala Arg Gly Lys Leu Ala Ala Ala Thr Ser
 195 200 205
 Leu Pro Glu Asp Thr Val Arg Val Trp Phe Ser Asn Arg Arg Ala Lys
 210 215 220
 Trp Arg Arg Gln Glu Lys Leu Lys Trp Glu Ala Gln Leu Pro Gly Ala
 225 230 235 240
 Ser Gln Asp Leu Thr Ile Pro Lys Asn Ser Pro Gly Ile Ile Ser Ala
 245 250 255
 Gln Gln Ser Pro Gly Ser Val Pro Ser Ala Ala Leu Pro Val Leu Glu
 260 265 270
 Pro Leu Ser Pro Ser Phe Cys Gln Leu Cys Cys Gly Thr Ala Pro Gly
 275 280 285
 Arg Cys Ser Ser Asp Thr Ser Ser Gln Ala Tyr Leu Gln Pro Tyr Trp
 290 295 300

Asp Cys Gln Ser Leu Leu Pro Val Ala Ser Ser Ser Tyr Val Glu Phe			
305	310	315	320
Ala Cys Pro Ala Ser Pro Pro Ile Leu Cys Ile Ile			
	325	330	

<210> 5

<211> 1872

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (30)..(1337)

<400> 5

ggatccggag gctgccaacc agctccagc atg cag aac agt cac agc gga gtg	53
Met Gln Asn Ser His Ser Gly Val	
1	5

aat cag ctt ggt ggt gtc ttt gtc aac ggg cgg cca ctg ccg gac tcc	101	
Asn Gln Leu Gly Gly Val Phe Val Asn Gly Arg Pro Leu Pro Asp Ser		
10	15	20

acc cgg cag aag atc gta gag cta gct cac agc ggg gcc cgg ccg tgc	149		
Thr Arg Gln Lys Ile Val Glu Leu Ala His Ser Gly Ala Arg Pro Cys			
25	30	35	40

gac att tcc cga att ctg cag acc cat gca gat gca aaa gtc cag gtg	197	
Asp Ile Ser Arg Ile Leu Gln Thr His Ala Asp Ala Lys Val Gln Val		
45	50	55

ctg gac aat gaa aac gta tcc aac ggt tgt gtg agt aaa att ctg ggc	245	
Leu Asp Asn Glu Asn Val Ser Asn Gly Cys Val Ser Lys Ile Leu Gly		
60	65	70

agg tat tac gag act ggc tcc atc aga ccc agg gca atc gga ggg agt	293	
Arg Tyr Tyr Glu Thr Gly Ser Ile Arg Pro Arg Ala Ile Gly Gly Ser		
75	80	85

aag cca aga gtg gcg act cca gaa gtt gta agc aaa ata gcc cag tat	341	
Lys Pro Arg Val Ala Thr Pro Glu Val Val Ser Lys Ile Ala Gln Tyr		
90	95	100

aaa cgg gag tgc cct tcc atc ttt gct tgg gaa atc cga gac aga tta	389
Lys Arg Glu Cys Pro Ser Ile Phe Ala Trp Glu Ile Arg Asp Arg Leu	

105	110	115	120	
tta tcc gag ggg gtc tgt acc aac gat aac ata ccc agt gtg tca tca				437
Leu Ser Glu Gly Val Cys Thr Asn Asp Asn Ile Pro Ser Val Ser Ser				
125		130		135
ata aac aga gtt ctt cgc aac ctg gct agc gaa aag caa cag atg ggc				485
Ile Asn Arg Val Leu Arg Asn Leu Ala Ser Glu Lys Gln Gln Met Gly				
140		145		150
gca gac ggc atg tat gat aaa cta agg atg ttg aac ggg cag acc gga				533
Ala Asp Gly Met Tyr Asp Lys Leu Arg Met Leu Asn Gly Gln Thr Gly				
155		160		165
agc tgg ggc aca cgc cct ggt tgg tat ccc ggg act tca gta cca ggg				581
Ser Trp Gly Thr Arg Pro Gly Trp Tyr Pro Gly Thr Ser Val Pro Gly				
170		175		180
caa ccc acg caa gat ggc tgc cag caa cag gaa gga ggg gga gag aac				629
Gln Pro Thr Gln Asp Gly Cys Gln Gln Glu Gly Gly Glu Asn				
185		190		195
acc aac tcc atc agt tct aac gga gaa gac tcg gat gaa gct cag atg				677
Thr Asn Ser Ile Ser Ser Asn Gly Glu Asp Ser Asp Glu Ala Gln Met				
205		210		215
cga ctt cag ctg aag cgg aag ctg caa aga aat aga aca tct ttt acc				725
Arg Leu Gln Leu Lys Arg Lys Leu Gln Arg Asn Arg Thr Ser Phe Thr				
220		225		230
caa gag cag att gag gct ctg gag aaa gag ttt gag agg acc cat tat				773
Gln Glu Gln Ile Glu Ala Leu Glu Lys Glu Phe Glu Arg Thr His Tyr				
235		240		245
cca gat gtg ttt gcc cgg gaa aga cta gca gcc aaa ata gat cta cct				821
Pro Asp Val Phe Ala Arg Glu Arg Leu Ala Ala Lys Ile Asp Leu Pro				
250		255		260
gaa gca aga ata cag gta tgg ttt tct aat cga agg gcc aaa tgg aga				869
Glu Ala Arg Ile Gln Val Trp Phe Ser Asn Arg Arg Ala Lys Trp Arg				
265		270		275
aga gaa gag aaa ctg agg aac cag aga aga cag gcc agc aac act cct				917
Arg Glu Glu Lys Leu Arg Asn Gln Arg Arg Gln Ala Ser Asn Thr Pro				
285		290		295
agt cac att cct atc agc agc agc ttc agt acc agt gtc tac cag cca				965
Ser His Ile Pro Ile Ser Ser Phe Ser Thr Ser Val Tyr Gln Pro				

300	305	310	
atc cca cag ccc acc aca cct gtc tcc tcc ttc aca tca ggt tcc atg Ile Pro Gln Pro Thr Thr Pro Val Ser Ser Phe Thr Ser Gly Ser Met			1013
315	320	325	
ttg ggc cga aca gac acc gcc ctc acc aac acg tac agt gct ttg cca Leu Gly Arg Thr Asp Thr Ala Leu Thr Asn Thr Tyr Ser Ala Leu Pro			1061
330	335	340	
ccc atg ccc agc ttc acc atg gca aac aac ctg cct atg caa ccc cca Pro Met Pro Ser Phe Thr Met Ala Asn Asn Leu Pro Met Gln Pro Pro			1109
345	350	355	360
gtc ccc agt cag acc tcc tca tac tcg tgc atg ctg ccc acc agc ccg Val Pro Ser Gln Thr Ser Ser Tyr Ser Cys Met Leu Pro Thr Ser Pro			1157
365	370	375	
tca gtg aat ggg cgg agt tat gat acc tac acc cct ccg cac atg caa Ser Val Asn Gly Arg Ser Tyr Asp Thr Tyr Thr Pro Pro His Met Gln			1205
380	385	390	
aca cac atg aac agt cag ccc atg ggc acc tcg ggg acc act tca aca Thr His Met Asn Ser Gln Pro Met Gly Thr Ser Gly Thr Thr Ser Thr			1253
395	400	405	
gga ctc att tca cct gga gtg tca gtt ccc gtc caa gtt ccc ggg agt Gly Leu Ile Ser Pro Gly Val Ser Val Pro Val Gln Val Pro Gly Ser			1301
410	415	420	
gaa cct gac atg tct cag tac tgg cct cga tta cag taaagagaga Glu Pro Asp Met Ser Gln Tyr Trp Pro Arg Leu Gln			1347
425	430	435	
aggagagagc atgtgatcga gagaggaaat tgtgttcaact ctgccaatga ctatgtggac			1407
acagcagttg ggtattcagg aaagaaaagag aaatggcggt tagaagcact tcactttgta			1467
actgtcctga actggagccc ggaaatggac tagaacccaag gaccttgctgt acagaaggca			1527
cggtatcagt tggaaccaaat cttcattttg gtatccaaac ttttattcat tttgggttat			1587
tatttgtaaa tgggcattgg tatgttataa tgaagaaaag aacaacacag gctgttggat			1647
cgcggatctg tgttgctcat gtgggtttaa aaaggaaacc atgatcgaca agatttgcca			1707
tggatttaag agttttatca agatatatca aatacttctc cccatctgtt catagtttat			1767

ggactgatgt tccaaagttt gatcattcct ttgcataataa ttgaacctgg gacaacacac 1827

actagatata tgtaaaaact atctgttgtt tttccaaagg ttgtt 1872

<210> 6

<211> 436

<212> PRT

<213> Mus musculus

<400> 6

Met Gln Asn Ser His Ser Gly Val Asn Gln Leu Gly Gly Val Phe Val
1 5 10 15

Asn Gly Arg Pro Leu Pro Asp Ser Thr Arg Gln Lys Ile Val Glu Leu
20 25 30

Ala His Ser Gly Ala Arg Pro Cys Asp Ile Ser Arg Ile Leu Gln Thr
35 40 45

His Ala Asp Ala Lys Val Gln Val Leu Asp Asn Glu Asn Val Ser Asn
50 55 60

Gly Cys Val Ser Lys Ile Leu Gly Arg Tyr Tyr Glu Thr Gly Ser Ile
65 70 75 80

Arg Pro Arg Ala Ile Gly Gly Ser Lys Pro Arg Val Ala Thr Pro Glu
85 90 95

Val Val Ser Lys Ile Ala Gln Tyr Lys Arg Glu Cys Pro Ser Ile Phe
100 105 110

Ala Trp Glu Ile Arg Asp Arg Leu Leu Ser Glu Gly Val Cys Thr Asn
115 120 125

Asp Asn Ile Pro Ser Val Ser Ser Ile Asn Arg Val Leu Arg Asn Leu
130 135 140

Ala Ser Glu Lys Gln Gln Met Gly Ala Asp Gly Met Tyr Asp Lys Leu
145 150 155 160

Arg Met Leu Asn Gly Gln Thr Gly Ser Trp Gly Thr Arg Pro Gly Trp
165 170 175

Tyr Pro Gly Thr Ser Val Pro Gly Gln Pro Thr Gln Asp Gly Cys Gln
180 185 190

Gln Gln Glu Gly Gly Glu Asn Thr Asn Ser Ile Ser Ser Asn Gly

195	200	205
Glu Asp Ser Asp Glu Ala Gln Met Arg Leu Gln Leu Lys Arg Lys Leu		
210	215	220
Gln Arg Asn Arg Thr Ser Phe Thr Gln Glu Gln Ile Glu Ala Leu Glu		
225	230	235
Lys Glu Phe Glu Arg Thr His Tyr Pro Asp Val Phe Ala Arg Glu Arg		
245	250	255
Leu Ala Ala Lys Ile Asp Leu Pro Glu Ala Arg Ile Gln Val Trp Phe		
260	265	270
Ser Asn Arg Arg Ala Lys Trp Arg Arg Glu Glu Lys Leu Arg Asn Gln		
275	280	285
Arg Arg Gln Ala Ser Asn Thr Pro Ser His Ile Pro Ile Ser Ser Ser		
290	295	300
Phe Ser Thr Ser Val Tyr Gln Pro Ile Pro Gln Pro Thr Thr Pro Val		
305	310	315
Ser Ser Phe Thr Ser Gly Ser Met Leu Gly Arg Thr Asp Thr Ala Leu		
325	330	335
Thr Asn Thr Tyr Ser Ala Leu Pro Pro Met Pro Ser Phe Thr Met Ala		
340	345	350
Asn Asn Leu Pro Met Gln Pro Pro Val Pro Ser Gln Thr Ser Ser Tyr		
355	360	365
Ser Cys Met Leu Pro Thr Ser Pro Ser Val Asn Gly Arg Ser Tyr Asp		
370	375	380
Thr Tyr Thr Pro Pro His Met Gln Thr His Met Asn Ser Gln Pro Met		
385	390	395
Gly Thr Ser Gly Thr Thr Ser Thr Gly Leu Ile Ser Pro Gly Val Ser		
405	410	415
Val Pro Val Gln Val Pro Gly Ser Glu Pro Asp Met Ser Gln Tyr Trp		
420	425	430
Pro Arg Leu Gln		
435		

<210> 7
<211> 861
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (160)..(801)

<400> 7
attctttga gtcgggagaa ctaggttaaca attcgaaaac tccaaagggt ggatgagggg 60
cgcgccccgt gtgtgtgggg gatactctgg tccccctgc agtacccctc aagtcagagg 120
ctggcacaca cacacccccc atttttcccc aaccgcagg atg gcg cct cat ccc 174
Met Ala Pro His Pro
1 5
ttg gat gcg ctc acc atc caa gtg tcc cca gag aca caa cct ttt 222
Leu Asp Ala Leu Thr Ile Gln Val Ser Pro Glu Thr Gln Gln Pro Phe
10 15 20
ccc gga gcc tcg gac cac gaa gtg ctc agt tcc aat tcc acc cca cct 270
Pro Gly Ala Ser Asp His Glu Val Leu Ser Ser Asn Ser Thr Pro Pro
25 30 35
agc ccc act ctc ata cct agg gac tgc tcc gaa gca gaa gtg ggt gac 318
Ser Pro Thr Leu Ile Pro Arg Asp Cys Ser Glu Ala Glu Val Gly Asp
40 45 50
tgc cga ggg acc tcg agg aag ctc cgc gcc cga cgc gga ggg cgc aac 366
Cys Arg Gly Thr Ser Arg Lys Leu Arg Ala Arg Arg Gly Gly Arg Asn
55 60 65
agg ccc aag agc gag ttg gca ctc agc aaa cag cga aga agc cgg cgc 414
Arg Pro Lys Ser Glu Leu Ala Leu Ser Lys Gln Arg Arg Ser Arg Arg
70 75 80 85
aag aag gcc aat gat cgg gag cgc aat cgc atg cac aac ctc aac tcg 462
Lys Lys Ala Asn Asp Arg Glu Arg Asn Arg Met His Asn Leu Asn Ser
90 95 100
gcg ctg gat gcg ctg cgc ggt gtc ctg ccc acc ttc ccg gat gac gcc 510
Ala Leu Asp Ala Leu Arg Gly Val Leu Pro Thr Phe Pro Asp Asp Ala
105 110 115
aaa ctt aca aag atc gag acc ctg cgc ttc gcc cac aac tac atc tgg 558

Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala His Asn Tyr Ile Trp
 120 125 130

gca ctg act cag acg ctg cgc ata gcg gac cac agc ttc tat ggc ccg 606
 Ala Leu Thr Gln Thr Leu Arg Ile Ala Asp His Ser Phe Tyr Gly Pro
 135 140 145

gag ccc cct gtg ccc tgt gga gag ctg ggg agc ccc gga ggt ggc tcc 654
 Glu Pro Pro Val Pro Cys Gly Glu Leu Gly Ser Pro Gly Gly Ser
 150 155 160 165

aac ggg gac tgg ggc tct atc tac tcc cca gtc tcc caa gcg ggt aac 702
 Asn Gly Asp Trp Gly Ser Ile Tyr Ser Pro Val Ser Gln Ala Gly Asn
 170 175 180

ctg agc ccc acg gcc tca ttg gag gaa ttc cct ggc ctg cag gtg ccc 750
 Leu Ser Pro Thr Ala Ser Leu Glu Glu Phe Pro Gly Leu Gln Val Pro
 185 190 195

agc tcc cca tcc tat ctg ctc ccg gga gca ctg gtg ttc tca gac ttc 798
 Ser Ser Pro Ser Tyr Leu Leu Pro Gly Ala Leu Val Phe Ser Asp Phe
 200 205 210

ttg tgaagagacc tgtctggctc tgggtgggtgg gtgctagtgg aaagggaggg 851
 Leu

gaccacagcc 861

<210> 8

<211> 214

<212> PRT

<213> Mus musculus

<400> 8

Met Ala Pro His Pro Leu Asp Ala Leu Thr Ile Gln Val Ser Pro Glu
 1 5 10 15

Thr Gln Gln Pro Phe Pro Gly Ala Ser Asp His Glu Val Leu Ser Ser
 20 25 30

Asn Ser Thr Pro Pro Ser Pro Thr Leu Ile Pro Arg Asp Cys Ser Glu
 35 40 45

Ala Glu Val Gly Asp Cys Arg Gly Thr Ser Arg Lys Leu Arg Ala Arg
 50 55 60

Arg Gly Gly Arg Asn Arg Pro Lys Ser Glu Leu Ala Leu Ser Lys Gln

65	70	75	80
Arg Arg Ser Arg Arg Lys Lys Ala Asn Asp Arg Glu Arg Asn Arg Met			
85		90	95
His Asn Leu Asn Ser Ala Leu Asp Ala Leu Arg Gly Val Leu Pro Thr			
100	105	110	
Phe Pro Asp Asp Ala Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala			
115	120	125	
His Asn Tyr Ile Trp Ala Leu Thr Gln Thr Leu Arg Ile Ala Asp His			
130	135	140	
Ser Phe Tyr Gly Pro Glu Pro Pro Val Pro Cys Gly Glu Leu Gly Ser			
145	150	155	160
Pro Gly Gly Ser Asn Gly Asp Trp Gly Ser Ile Tyr Ser Pro Val			
165	170	175	
Ser Gln Ala Gly Asn Leu Ser Pro Thr Ala Ser Leu Glu Glu Phe Pro			
180	185	190	
Gly Leu Gln Val Pro Ser Ser Pro Ser Tyr Leu Leu Pro GLY Ala Leu			
195	200	205	
Val Phe Ser Asp Phe Leu			
210			

<210> 9
<211> 21
<212> DNA
<213> Mus musculus

<400> 9
ttcggctatg acatcggtgt g

21

<210> 10
<211> 21
<212> DNA
<213> Mus musculus

<400> 10
agctgaggcc agcaatctga c

21

<210> 11
<211> 18
<212> DNA
<213> *Mus musculus*

<400> 11
cagcccttag tgaccagc

18

<210> 12
<211> 18
<212> DNA
<213> *Mus musculus*

<400> 12
atgctgggtgc agcactga

18

<210> 13
<211> 18
<212> DNA
<213> *Mus musculus*

<400> 13
cgccctgatcc cttggatg

18

<210> 14
<211> 18
<212> DNA
<213> *Mus musculus*

<400> 14
cagtcaccca cttctgct

18

<210> 15
<211> 20
<212> DNA
<213> *Mus musculus*

<400> 15
ctttcccgta gatgaaatcc

20

<210> 16
<211> 21

<212> DNA
<213> Mus musculus

<400> 16
gtcaaggttca acatcaactgc c

21

<210> 17
<211> 20
<212> DNA
<213> Mus musculus

<400> 17
gtttgtacgg gatcaaatgc

20

<210> 18
<211> 20
<212> DNA
<213> Mus musculus

<400> 18
atgctgcgtt tcttgtcatt

20

<210> 19
<211> 20
<212> DNA
<213> Mus musculus

<400> 19
tcactgtgcc tgaacttacc

20

<210> 20
<211> 20
<212> DNA
<213> Mus musculus

<400> 20
ggaacatagc cgtaaaactgc

20

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/086107 A3

(51) International Patent Classification⁷: C12N 5/08, 5/02, A61K 35/39, 35/48, C12Q 1/02, A61P 5/48

(74) Agents: WEICKMANN, Franz, Albert et al.; Weickmann & Weickmann, Postfach 86 08 20, 81635 München (DE).

(21) International Application Number: PCT/EP02/04362

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 19 April 2002 (19.04.2002)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/284,531 19 April 2001 (19.04.2001) US

(71) Applicants (*for all designated States except US*):
DEVELOGEN AKTIENGESELLSCHAFT FÜR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG [DE/DE]; Rudolf-Wissell-Strasse 28, 37079 Göttingen (DE). INSTITUT FÜR PFLANZENGENETIK UND KULTURPFLANZENFORSCHUNG [DE/DE]; Corrensstrasse 3, 06466 Gatersleben (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): WOBUS, Anna, M. [DE/DE]; Liebigweg 7, 06466 Gatersleben (DE). ST-ONGE, Luc [CA/DE]; Rautenbreite 5, 37077 Göttingen (DE). BLYSZCZUK, Przemyslaw [PL/DE]; Corrensstrasse 4a, 06466 Gatersleben (DE). HOFFMANN, Ursula [DE/DE]; Schedener Weg 28, 37127 Jühnde (DE).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

(88) Date of publication of the international search report:
24 July 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/086107 A3

(54) Title: A METHOD FOR DIFFERENTIATING STEM CELLS INTO INSULIN-PRODUCING CELLS

(57) Abstract: The present invention relates a novel method for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical (particularly diabetes) field that directly arise from the method of the invention. Additionally, the present invention relates to applications for identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.

A. CLASSIFICATION OF SUBJECT MATTER	IPC 7 C12N5/08	C12N5/02	A61K35/39	A61K35/48	C12Q1/02
	A61P5/48				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SORIA B ET AL: "Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice" DIABETES, vol. 49, no. 2, February 2000 (2000-02), pages 157-162, XP002183378 ISSN: 0012-1797 cited in the application the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-32

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

27 March 2003

Date of mailing of the International search report

09/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category	Citation of document, with indication, where appropriate, of the relevant passages	
X, P	LUMELSKY N ET AL: "Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets" SCIENCE, vol. 292, no. 5520, 18 May 2001 (2001-05-18), pages 1389-1394, XP002183377 ISSN: 0036-8075 cited in the application the whole document ---	1-32
E	WO 02 059278 A (KIM JONG-HOON ;BLONDEL OLIVER (US); MC KAY RONALD D (US); GOVERNME) 1 August 2002 (2002-08-01) examples ---	1-32
X, P	ASSADY S ET AL: "Insulin production by human embryonic stem cells." DIABETES, vol. 50, no. 8, August 2001 (2001-08), pages 1691-1697, XP002233758 ISSN: 0012-1797 cited in the application the whole document ---	1-32
X	ST-ONGE L ET AL: "Pancreas development and diabetes." CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 9, no. 3, June 1999 (1999-06), pages 295-300, XP002233759 ISSN: 0959-437X cited in the application table 1 ---	1-32
X	GRAPIN-BOTTON A ET AL: "Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes." GENES & DEVELOPMENT, vol. 15, no. 4, 15 February 2001 (2001-02-15), pages 444-454, XP002233760 ISSN: 0890-9369 the whole document ---	1-32
X, P	SORIA B: "In-vitro differentiation of pancreatic beta-cells." DIFFERENTIATION, vol. 68, no. 4-5, October 2001 (2001-10), pages 205-219, XP002233761 ISSN: 0301-4681 the whole document ---	1-32
	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>BLYSZCZUK P ET AL: "Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 3, 4 February 2003 (2003-02-04), pages 998-1003, XP002233762 ISSN: 0027-8424</p> <p>-----</p>	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02059278	A 01-08-2002	WO 02059278 A2	01-08-2002